Idelalisib a favorable treatment option for pretreated relapsed or refractory CLL in the absence of alternativesAugust 19, 2023B Cell Lymphoma
Zanubrutinib and obinutuzumab combo shows promise for relapsed or refractory FLAugust 19, 2023B Cell Lymphoma
Rituximab plus chemotherapy vs chemotherapy alone improves survival in untreated advanced-stage MCLAugust 19, 2023B Cell Lymphoma
Combination of MIPI, Ki-67, and p53 expression defines a high-risk group in MCLAugust 19, 2023B Cell Lymphoma
Final phase 2 results favor acalabrutinib therapy in relapsed or refractory MCLAugust 19, 2023B Cell Lymphoma
Bruton tyrosine kinase inhibitors improve outcomes in CLL when combined with anti-CD20 mAbJuly 22, 2023B Cell Lymphoma
A lymph node diameter > 56.5 mm strongly predicts progression during venetoclax treatment in CLLJuly 22, 2023B Cell Lymphoma
Soluble CD163 holds prognostic value in chemoimmunotherapy- and targeted therapy-treated MCLJuly 22, 2023B Cell Lymphoma
First-line ibrutinib an effective treatment for patients with CLL carrying TP53 aberrationsJuly 22, 2023B Cell Lymphoma
Front-line rituximab+lenalidomide an up-and-coming therapy for elderly frail patients with DLBCLJuly 22, 2023B Cell Lymphoma
Nivolumab+brentuximab vedotin offers a salvage treatment option for relapsed or refractory PMBLJuly 22, 2023B Cell Lymphoma
A patient subgroup with high-risk features shows early bendamustine treatment failure in mantle cell lymphomaJuly 22, 2023B Cell Lymphoma
